IQV$203.77
$200.667
Chart
Performance
Key Stats
AI IQV Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyIQVIA Holdings Inc. demonstrates solid fundamental strength with consistent revenue and profit growth, a healthy balance sheet, and strong cash flow. While valuation appears moderately stretched and short-term technicals show some overbought conditions, the company's market position and growth potential in healthcare intelligence and clinical research provide a compelling investment case.
Thematic
IQVIA is well-positioned to benefit from secular trends in healthcare, including the increasing demand for real-world evidence, data analytics in life sciences, and the outsourcing of clinical trials. The company's focus on technology and data solutions aligns with the growing digitalization of healthcare.
Fundamental
IQVIA exhibits strong financial health with robust revenue growth, improving profitability, a manageable debt load, and consistent free cash flow generation. The company's balance sheet is solid, and its ability to convert revenue into profit is commendable.
Technical
The stock is currently trading around its 52-week high, indicating a positive short-term trend. However, several oscillators suggest the stock may be overbought, hinting at a potential for a short-term consolidation or pullback.
| Factor | Score |
|---|---|
| Healthcare Data & Analytics | 85 |
| Clinical Trial Outsourcing | 75 |
| Digital Health Transformation | 65 |
| Regulatory Environment (Healthcare) | 60 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 80 |
| Growth | 75 |
| Balance Sheet Health | 70 |
| Cash Flow | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 40 |
| Volume Confirmation | 60 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Beat
The company has consistently beaten EPS estimates for the last several quarters, including a 0.38% beat in Q1 2025 and a 2.57% beat in Q2 2025, indicating strong operational execution and earnings power.
Reasonable P/E Ratio
The trailing P/E ratio of 29.06 is within a reasonable range, especially considering the company's revenue growth and market position. While not cheap, it doesn't appear excessively overvalued on this metric.
Bearish Points (7)
High Quarterly P/S Ratio
The quarterly P/S ratio for Q1 2025 is 7.8, which is significantly higher than the trailing P/S ratio, suggesting potential overvaluation based on recent sales performance.
Slowing Revenue Growth Trends
While annual revenue has grown, quarterly revenue growth appears to be slowing. Q2 2025 projected revenue of $4.017B shows modest growth compared to previous periods, with a declining net margin in the same quarter.
Calendar
July 2025
22
Next Earnings Date
H: $3.05
A: $2.98
L: $2.92
H: 4.11B
A: 4.08B
L: 4.03B
Profile
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.
Seasonals
Price Target
208.17 USD
The 39 analysts offering 1 year price forecasts for IQV have a max estimate of 268.43 and a min estimate of 160.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
A leading global Contract Research Organization (CRO), providing clinical research services directly competitive with IQVIA's core offerings.
Weight: 95
Owns PPD, a major Contract Research Organization (CRO), making it a direct competitor to IQVIA in clinical trial services.
Weight: 92
Owns Covance, a major Contract Research Organization (CRO), directly competing with IQVIA in clinical development and lab services.
Weight: 90
A leading provider of drug discovery, preclinical development, and clinical support services, complementing and at times competing with IQVIA's early-stage services.